Evaluation of ultrasensitive cardiac Troponin I levels in patients with breast cancer during chemotherapy

Clinica Chimica Acta

Volumn 428, Issue , 2014, Pages 70-71

  Moreno, Ricardo ^a   Costa, Renata G ^a   Mazar, Renata C ^a   Silva, Mayra B ^a   De Souza, Mariana G ^a   Murad, Neif ^a   Feder, David ^a   Azzalis, Ligia A ^b   Alves, Beatriz C A ^a   Gehrke, Flavia S ^a   Adami, Fernando ^a   Fonseca, Fernando L A ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE; TRASTUZUMAB; TROPONIN I; ULTRASENSITIVE CARDIAC TROPONIN I; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; DRUG SAFETY; HEART INJURY; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; BLOOD; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; FEMALE; HEART INJURIES; MIDDLE AGED;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HEART INJURIES; HUMANS; MIDDLE AGED; TROPONIN I;

EID: 84888126726     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.11.001     Document Type: Letter

References (11)

1. Instituto Nacional do Câncer Estimativa 2012: Incidência de Câncer no Brasil. Rio de Janeiro 2012, INCA, [http://www.inca.gov.br. Acessed in march 10th 2013].
2. Sawaya H., Sebag I.A., Plana J.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012, 5:596-603.
3. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
4. Shi Y., Moon M., Dawood S., McManus B., Liu P.P. Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011, 36:296-305.
5. Steinherz L.J., Steinherz P.G., Tan C.T.C., Heller G., Murphy M.L. Cardiac toxicity 4 to 20years after completing anthracycline therapy. J A M A 1999, 266:1672-1677.
6. Wallace K.B., Hausner E., Herman E., et al. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004, 32:106-121.
7. Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
8. Morris P.G., Chen C., Steingart R., et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating Trastuzumab and Lapatinib. Clin Cancer Res 2011, 17:3490-3499.
9. Fallah-Rad N., Walker J.R., Wassef A., et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011, 57:2263-2270.
10. Bryant J., Picot J., Baxter L., Levitt G., Sullivan I., Clegg A. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Br J Cancer 2007, 96:226-230.
11. Sawaya H., Sebag I.A., Plana J.C., et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011, 107:1375-1380.